How to build flexibility into your CGT manufacturing process while maintaining regulatory compliance
With only 5%-10% of the manufacturing capacity needed to commercialise cell and gene therapy (CGT) products at scale currently available, CGT innovators face a critical challenge: how to rapidly scale flexible production processes without compromising the rigorous compliance standards that patient lives depend on.
